Business Context and Reporting Period
This Form 8-K Current Report was filed by Spero Therapeutics, Inc. on April 18, 2019. The report addresses a corporate governance event regarding the departure of a director and the subsequent appointment of a consultant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Departure: David P. Southwell notified the Company of his decision to step down from the Board of Directors, effective April 25, 2019.
- Reason for Departure: Mr. Southwell is resigning due to contractual obligations associated with his new appointment as CEO of another operating company. The filing explicitly states there is no disagreement with the Company regarding operations, policies, or practices.
- Consulting Arrangement: Concurrent with his resignation, Mr. Southwell entered into a Consulting Agreement effective April 25, 2019.
- Compensation Terms: Mr. Southwell will receive annual compensation of $35,000, payable quarterly in arrears, for up to 60 hours of advisory services per year.
- Equity Status: Mr. Southwell's outstanding stock options will remain exercisable and continue to vest as long as the Consulting Agreement remains in effect.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business strategy. No specific risks or contingencies related to financial performance are disclosed in this document. The Consulting Agreement is intended to be filed as an exhibit to the Quarterly Report on Form 10-Q for the period ending June 30, 2019.
Investor Verification Checklist
- Verify the effective date of the Board vacancy (April 25, 2019) and any subsequent Board appointments.
- Review the full text of the Consulting Agreement when filed as an exhibit to the Q2 2019 Form 10-Q for complete terms.
- Confirm the status of Mr. Southwell's stock options and vesting schedule post-resignation.
- Monitor future filings for any impact on the Company's strategic direction following the departure of a director.